Related references
Note: Only part of the references are listed.Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
Roy Fleischmann et al.
RHEUMATOLOGY AND THERAPY (2019)
CXCL10 is upregulated in synovium and cartilage following articular fracture
Bridgette D. Furman et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2018)
K/BxN Serum-Transfer Arthritis as a Model for Human inflammatory Arthritis
Anne D. Christensen et al.
FRONTIERS IN IMMUNOLOGY (2016)
Anti-TNF therapy: past, present and future
Claudia Monaco et al.
INTERNATIONAL IMMUNOLOGY (2015)
Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse
Jinhyun Kim et al.
ARTHRITIS RESEARCH & THERAPY (2014)
A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis
Daniela S. Herzig et al.
CRITICAL CARE (2012)
Evaluation of the Safety of Rituximab in Combination With a Tumor Necrosis Factor Inhibitor and Methotrexate in Patients With Active Rheumatoid Arthritis Results From a Randomized Controlled Trial
Maria W. Greenwald et al.
ARTHRITIS AND RHEUMATISM (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis
Eun Young Lee et al.
ARTHRITIS RESEARCH & THERAPY (2011)
A Comparison of Patient Characteristics and Outcomes in Selected European and US Rheumatoid Arthritis Registries
Jeffrey R. Curtis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms
Rosa Elena Navarro-Hernandez et al.
DISEASE MARKERS (2009)
Reciprocal cross-talk between RANKL and interferon-γ-inducible protein 10 is responsible for bone-erosive experimental arthritis
Han Bok Kwak et al.
ARTHRITIS AND RHEUMATISM (2008)
Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis
Karkada Mohan et al.
JOURNAL OF IMMUNOLOGY (2007)
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
Michael Weinblatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
MC Genovese et al.
ARTHRITIS AND RHEUMATISM (2004)
Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols
E Douni et al.
ARTHRITIS RESEARCH & THERAPY (2004)
A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis
R Hanaoka et al.
ARTHRITIS RESEARCH & THERAPY (2003)
CXCR3 and CCR5 ligands in rheumatoid arthritis synovium
DD Patel et al.
CLINICAL IMMUNOLOGY (2001)
Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium
T Nanki et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
